Drug Trial Radar · NCT07405177
A Study of MK-7240 in Healthy Participants (MK-7240-009)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Mar 5, 2026
Primary completion
Sep 19, 2026
Study completion Oct 12, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
Conditions
- Healthy
Interventions
Tulisokibart Form 1Biological
Solution for injection.
Tulisokibart Form 2Biological
Solution for injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of TulisokibartTime frame: At designated timepoints up to 14 weeks
- Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of TulisokibartTime frame: At designated timepoints up to 14 weeks
- Maximum Plasma Concentration (Cmax) of TulisokibartTime frame: At designated timepoints up to 14 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nucleus Network ( Site 0002)
Brisbane, Queensland, Australia
Nucleus Network ( Site 0001)
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.